Related Experiment Video
Updated: Jun 27, 2026
Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
[Characteristic of the yeast isolated from patients with leukaemia]
Abstract:
It has been shown that biotopes of upper respiratory system and intestine were contaminated with yeast in 44.6% of patients with leukaemia (of 112 examined ones). Their quantity exceeds the boundary value for practically healthy people and is > or = 10(2) KOE/ml in the nasal activity and fauces and < or = 10(4) KOE/g in the intestine. It was established that in patients with leucemia the mycotic complications are mainly caused by anamorphous yeast of ascomycetic affinity. Candida albicans, as well as C. glabrata, C. rugosa and Candida sp. play the leading role. The Candida genus species are mainly sensitive to amphotericine B, clotrisamol and nistatin.
Insights
Yeast contamination is common in leukemia patients, affecting the respiratory tract and intestines. Fungal infections in these patients are primarily caused by Candida species, which show sensitivity to specific antifungal medications.
Area of Science:
- Medical Mycology
- Hematology
- Infectious Diseases
Context:
- Leukemia patients exhibit a high prevalence of yeast colonization in the upper respiratory tract and intestines.
- Quantification reveals elevated yeast levels exceeding normal thresholds in nasal passages, fauces, and intestinal biotopes.
Purpose:
- To investigate the prevalence and types of yeast contamination in leukemia patients.
- To identify the etiological agents responsible for mycotic complications in leukemia.
- To determine the antifungal susceptibility profiles of prevalent yeast species.
Summary:
- Yeast contamination was observed in 44.6% of 112 leukemia patients, with significant levels in the respiratory and intestinal systems.
- Anamorphic yeasts, particularly Candida species (e.g., Candida albicans, C. glabrata, C. rugosa), are the primary cause of fungal infections.
- The study identified key Candida species and their sensitivity to amphotericin B, clotrimazole, and nystatin.
Impact:
- Highlights the significant risk of yeast colonization and subsequent fungal infections in immunocompromised leukemia patients.
- Provides crucial data for guiding antifungal therapy selection in this vulnerable population.
- Informs clinical management strategies to prevent and treat mycotic complications in leukemia care.
